Literature DB >> 17387214

Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Christopher H Goss1, Jane L Burns.   

Abstract

With the improving survival of patients with cystic fibrosis (CF), the clinical spectrum of this complex multisystem disease continues to evolve. One of the most important clinical events for patients with CF in the course of this disease is an acute pulmonary exacerbation. Clinical and microbial epidemiology studies of CF pulmonary exacerbations continue to provide important insight into the course, prognosis and complications of the disease. This review provides a summary of the pathophysiology, clinical epidemiology and microbial epidemiology of a CF pulmonary exacerbation.

Entities:  

Mesh:

Year:  2007        PMID: 17387214      PMCID: PMC2092469          DOI: 10.1136/thx.2006.060889

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  117 in total

1.  Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.

Authors:  Ronald L Gibson; Julia Emerson; Sharon McNamara; Jane L Burns; Margaret Rosenfeld; Ann Yunker; Nicole Hamblett; Frank Accurso; Mark Dovey; Peter Hiatt; Michael W Konstan; Richard Moss; George Retsch-Bogart; Jeffrey Wagener; David Waltz; Robert Wilmott; Pamela L Zeitlin; Bonnie Ramsey
Journal:  Am J Respir Crit Care Med       Date:  2002-12-12       Impact factor: 21.405

2.  Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Julia Emerson; Christopher H Goss; Moira L Aitken
Journal:  Am J Respir Crit Care Med       Date:  2002-08-15       Impact factor: 21.405

3.  Safety and use of sputum induction in children with cystic fibrosis.

Authors:  Ranjan Suri; Lindsay J Marshall; Colin Wallis; Christopher Metcalfe; Janis K Shute; Andrew Bush
Journal:  Pediatr Pulmonol       Date:  2003-04

4.  Absent secretion to vasoactive intestinal peptide in cystic fibrosis airway glands.

Authors:  Nam Soo Joo; Toshiya Irokawa; Jin V Wu; Robert C Robbins; Richard I Whyte; Jeffrey J Wine
Journal:  J Biol Chem       Date:  2002-10-03       Impact factor: 5.157

5.  Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis.

Authors:  Arnold L Smith; Stanley B Fiel; Nicole Mayer-Hamblett; Bonnie Ramsey; Jane L Burns
Journal:  Chest       Date:  2003-05       Impact factor: 9.410

6.  Evaluation of MicroScan Autoscan for identification of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  Lisa Saiman; Jane L Burns; Davise Larone; Yunhua Chen; Elizabeth Garber; Susan Whittier
Journal:  J Clin Microbiol       Date:  2003-01       Impact factor: 5.948

7.  Alcaligenes infection in cystic fibrosis.

Authors:  Kenneth Tan; Steven P Conway; Keith G Brownlee; Christine Etherington; Daniel G Peckham
Journal:  Pediatr Pulmonol       Date:  2002-08

8.  Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.

Authors:  Julia Emerson; Margaret Rosenfeld; Sharon McNamara; Bonnie Ramsey; Ronald L Gibson
Journal:  Pediatr Pulmonol       Date:  2002-08

9.  Factors influencing outcomes in cystic fibrosis: a center-based analysis.

Authors:  Charles Johnson; Steven M Butler; Michael W Konstan; Wayne Morgan; Mary Ellen B Wohl
Journal:  Chest       Date:  2003-01       Impact factor: 9.410

10.  Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis.

Authors:  Christopher H Goss; Kelly Otto; Moira L Aitken; Gordon D Rubenfeld
Journal:  Am J Respir Crit Care Med       Date:  2002-08-01       Impact factor: 21.405

View more
  153 in total

1.  Analysis of changes in diversity and abundance of the microbial community in a cystic fibrosis patient over a multiyear period.

Authors:  Joshua R Stokell; Raad Z Gharaibeh; Timothy J Hamp; Malcolm J Zapata; Anthony A Fodor; Todd R Steck
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

2.  Serum procalcitonin is not an early marker of pulmonary exacerbation in children with cystic fibrosis.

Authors:  Jacoba Johanna Louw; Jaan Toelen; Marijke Proesmans; François Vermeulen; Jaak Billen; Kris de Boeck
Journal:  Eur J Pediatr       Date:  2011-06-01       Impact factor: 3.183

3.  Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.

Authors:  Edith T Zemanick; Brandie D Wagner; J Kirk Harris; Jeffery S Wagener; Frank J Accurso; Scott D Sagel
Journal:  Pediatr Pulmonol       Date:  2010-06

4.  Pulmonary exacerbations in cystic fibrosis and bronchiectasis.

Authors:  J S Elborn; S C Bell
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

5.  Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine responses in cystic fibrosis airway epithelial cells.

Authors:  Sangbrita S Chattoraj; Shyamala Ganesan; Andrew M Jones; Jennifer M Helm; Adam T Comstock; Rowland Bright-Thomas; John J LiPuma; Marc B Hershenson; Umadevi S Sajjan
Journal:  Thorax       Date:  2011-02-02       Impact factor: 9.139

Review 6.  Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?

Authors:  Bonnie W Ramsey
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

Review 7.  Crosstalk Between Lung and Extrapulmonary Organs in Infection and Inflammation.

Authors:  Zhihan Wang; Qinqin Pu; Canhua Huang; Min Wu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.

Authors:  Sonya L Heltshe; Christopher H Goss; Valeria Thompson; Scott D Sagel; Don B Sanders; Bruce C Marshall; Patrick A Flume
Journal:  Thorax       Date:  2015-04-24       Impact factor: 9.139

9.  Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1.

Authors:  Susanna A McColley; Michael W Konstan; Bonnie W Ramsey; J Stuart Elborn; Michael P Boyle; Claire E Wainwright; David Waltz; Montserrat Vera-Llonch; Gautham Marigowda; John G Jiang; Jaime L Rubin
Journal:  J Cyst Fibros       Date:  2018-08-23       Impact factor: 5.482

10.  Influenza-associated cystic fibrosis pulmonary exacerbations.

Authors:  Justin R Ortiz; Kathleen M Neuzil; John C Victor; Anna Wald; Moira L Aitken; Christopher H Goss
Journal:  Chest       Date:  2009-12-04       Impact factor: 9.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.